newsfilter
← Latest News
GlobeNewswire·

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today reports that the FDA's Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test